Since December 2019, SARS‐CoV‐2 has rapidly spread worldwide, challenging the clinician and focusing the entire globe on critical illness high mortality.1 Apart from common respiratory symptoms, patients often present with symptoms suggestive of SARS‐CoV‐2 neuroinvasiveness.2 Some are very general (like headache, nausea, or vomiting), while others are more specific, such as hypoacousis, agueusia, or anosmia. SARS‐CoV‐2 is suspected to enter the central nervous system through the olfactive bulb and to progress transsynaptically to the brain—a mechanism demonstrated in animal models of SARS‐CoV‐1 infection.